Declining Genomic Costs Will Expand Personalized Immunotherapies
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
05 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$100.00
67.4% undervalued intrinsic discount21 Aug
US$32.59
1Y
-11.7%7D
0.9%1Y
-11.7%7D
0.9%